COMMUNIQUÉS West-GlobeNewswire

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
23/05/2025
PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies [...]
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
23/05/2025
IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment [...]
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F
23/05/2025
Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, [...]
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
23/05/2025
HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the [...]
Polyrizon Announces Receipt of Nasdaq Delisting Notice
23/05/2025
Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Informations sur le nombre total de droits de vote et d'actions
23/05/2025
Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 23 mai 2025, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des [...]
Information on the total number of voting rights and shares
23/05/2025
Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 23, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large [...]
Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
23/05/2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 23, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”) announced [...]
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
24/05/2025
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. ( [...]
BioSig Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain.
24/05/2025
Los Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced it has signed a definitive share [...]
Cross Medical Group Introduces HydraFacial Treatments for Advanced Skin Rejuvenation
23/05/2025
The Philadelphia Area Team is Offering a New, Highly Customizable Skin Resurfacing Option Starting This Spring PHILADELPHIA and VILLANOVA, Pa., May 23, 2025 (GLOBE NEWSWIRE) -- Cross Medical Group is pleased to announce [...]
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
23/05/2025
WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced a planned expansion of TVGN 489’s target population to include patients 65 and older. As [...]
Boundless Bio Announces Portfolio Prioritization and Runway Extension
23/05/2025
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through [...]
Mind Body Peak Performance Rebrands to ‘High Performance Longevity’ Podcast, Integrating Biohacking with Ancestral Wisdom
23/05/2025
Austin, TX, May 23, 2025 (GLOBE NEWSWIRE) -- Outliyr, a performance health brand known for combining modern biohacking with ancestral wisdom, has rebranded its podcast—formerly Mind Body Peak Performance —as High [...]
Transactions of Managers and Closely Associated Persons
23/05/2025
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 95,000 shares in [...]
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.
23/05/2025
TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“ MediPharm ”, the “ Company ”, or “ we ”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its [...]
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
23/05/2025
WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA ® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer [...]
Sol-Gel Reports First Quarter 2025 Results
23/05/2025
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd . (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. [...]
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
23/05/2025
Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuations Successful completion of the [...]

Pages